BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, was recently featured on Uptick Newswire’s Stock Day Podcast. Dr. Bill Williams, BriaCell’s president and CEO, was interviewed for the podcast by Everett Jolly of Stock Day. Per the interview, Dr. Williams expressed his enthusiasm regarding the company’s future, as he believes BriaCell is on the cutting edge of cancer treatment with its effective and safe immunotherapy applications. Williams also detailed BriaCell’s current major programs: Bria-IMT, which is in the clinic right now, and Bria-OTS, which is in development. “BriaCell is developing the first off-the-shelf, personalized immunotherapy targeting advanced breast cancer,” Dr. Bill Williams, BriaCell’s president and CEO, stated during the interview. “We have a proprietary technology that allows us to target immune responses in breast cancer in a personalized fashion. (The solution) we are working towards is an off-the-shelf immunotherapy which is very similar in some ways to other successful targeted personalized immunotherapies that are not off-the-shelf, are costly, and have been associated with complex manufacturing.”
To listen to the full interview, visit http://nnw.fm/PoA5U
To view the full press release, visit http://nnw.fm/bEBm3
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com